日报更新时间：04-10 10:00
周报更新时间：04-11 03:39
今开价：142.31
最高价：142.35
成交量：923861.0
昨收价：142.85
最低价：139.46
最新价：140.72
中文名称：西雅图遗传学
英文名称：Seattle Genetics
行业：医疗
简介：Seattle Genetics, Inc.于1997年7月15日在美国特拉华州注册成立
电话：1-425-5274000
Seattle Genetics 是一个关注于研发与商业化创新型基于抗体疗法针对癌症的生物医药公司。这家公司在抗体偶联药物(ADCs)领域是行业领导者。ADCs是一项能够控制单克隆抗体的靶向能力（把杀死癌细胞的介质运送到目标处）的技术。ADCs技术可以靶向定位癌症细胞，而不对非靶细胞造成伤害，因而降低了传统化疗方法的毒性作用，同时潜在提高了抗肿瘤活性。Seattle Genetics公司的第一个ADC产品ADCETRIS® (brentuximab vedotin)已经成功在全球50个国家（包括美国，加拿大，日本，欧盟成员国）商业化，是第一个获批的ADCs新药。为了扩大ADCETRIS®的发展机遇，公司正在进行一项更广范围内的临床发展项目用以评估它在已经被批准的症状上的治疗潜力，同时也涵盖更广的领域，包括淋巴瘤和非淋巴瘤。Seattle Genetics正在和Takeda Pharmaceutical Company联合研发ADCETRIS®。基于这些联合效应，Seattle Genetics拥有在美国和加拿大的完全商业用权。Takeda拥有在其他国家商业化的专卖权。Seattle Genetics 较强的研发能力是公司创新与长期发展的引擎。Seattle Genetics 的ADC 技术也正在被内部与外部合作者广泛使用（超过20家ADCs临床研究项目在使用本公司的技术产权来增强抗体能力）。Seattle Genetics公司就其ADC技术与各种生物技术和制药公司开展合作，包括：AbbVie Biotechnology Ltd.; 拜耳制药公司; 武田药品有限公司; Celldex Therapeutics, Inc.; Genentech, Inc.（2009年被Roche收购）; GlaxoSmithKline LLC; 辉瑞公司; and Unum Therapeutics, Inc.，与Agensys, Inc. 和 Genmab A/S(NASDAQ:GEN)签署有共同开发协议。Seattle Genetics, Inc.产品及在研产品包括： 公司销售ADCETRIS(brentuximab vedotin)，一种抗体-药物结合物用于霍奇金淋巴瘤复发和复发的系统性间变性大细胞淋巴瘤的治疗。 开发SGN-CD33A，目前处于Ib期临床试验，用于初诊急性髓系白血病(AML)患者；同时处于I/II期临床试验，用于治疗复发或难治性白血病患者；还处于I/II期临床试验，用于未经治疗骨髓增生异常综合症状的患者；同时处于治疗白血病的I期临床试验阶段。 开发SGN-CD19A，目前处于II期临床试验，用于复发或难治性弥漫性大B细胞淋巴瘤的患者；以及用于复发或难治的B细胞非霍奇金淋巴瘤的I期临床试验阶段；复发或难治的B细胞急性淋巴细胞性白血病I期临床阶段。 SGN-LIV1A，用于LIV-1-阳性转移性乳腺癌的治疗的I期临床阶段。 SGN-CD70A，用于CD70阳性的肾细胞癌的治疗的I期临床试验阶段。 SEA-CD40，用于CD40阳性实体肿瘤的治疗的I期临床阶段。 ASG-22ME，用于Nectin-4阳性实体肿瘤（包括膀胱癌）的治疗的I期临床阶段。 ASG-15ME，用于膀胱癌的治疗。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2019-07-16 | Gryska (David W) | Director | Sell | 5000 | 75.00 |
| 2019-07-16 | Gryska (David W) | Director | Buy | 5000 | 12.76 |
| 2019-07-07 | Siegall (Clay B) | Chief Executive Officer | Sell | 14717 | 66.71 |
| 2019-07-07 | Siegall (Clay B) | Chief Executive Officer | Sell | 200 | 68.45 |
| 2019-07-07 | Siegall (Clay B) | Chief Executive Officer | Buy | 200 | 12.16 |
| 2019-07-07 | Siegall (Clay B) | Chief Executive Officer | Buy | 14717 | 12.16 |
| 2019-07-07 | Siegall (Clay B) | Chief Executive Officer | Sell | 5231 | 67.33 |
| 2019-07-07 | Siegall (Clay B) | Chief Executive Officer | Buy | 5231 | 12.16 |
| 2019-06-23 | Himes (Vaughn B) | Chief Technology Officer | Buy | 2268 | 44.09 |
| 2019-06-23 | Himes (Vaughn B) | Chief Technology Officer | Buy | 2436 | 41.04 |
| 2019-06-16 | Dansey (Roger D) | Officer | Sell | 5416 | 68.60 |
| 2019-06-09 | Siegall (Clay B) | Chief Executive Officer | Sell | 10950 | 69.13 |
| 2019-06-09 | Siegall (Clay B) | Chief Executive Officer | Sell | 2552 | 69.90 |
| 2019-06-09 | Siegall (Clay B) | Chief Executive Officer | Buy | 5746 | 12.16 |
| 2019-06-09 | Siegall (Clay B) | Chief Executive Officer | Sell | 5746 | 68.21 |
| 2019-06-09 | Siegall (Clay B) | Chief Executive Officer | Buy | 10950 | 12.16 |
| 2019-06-09 | Siegall (Clay B) | Chief Executive Officer | Buy | 900 | 12.16 |
| 2019-06-09 | Siegall (Clay B) | Chief Executive Officer | Gift | 2875 | -- |
| 2019-06-09 | Siegall (Clay B) | Chief Executive Officer | Sell | 900 | 70.98 |
| 2019-06-09 | Siegall (Clay B) | Chief Executive Officer | Buy | 2552 | 12.16 |
| 2019-06-05 | BAKER BROS ADVISORS L P | Beneficial Owner of More than 10% Class | Sell | 1002483 | -- |
| 2019-06-05 | BAKER BROS ADVISORS L P | Beneficial Owner of More than 10% Class | Buy | 74229 | -- |
| 2019-06-05 | BAKER BROS ADVISORS L P | Beneficial Owner of More than 10% Class | Buy | 74229 | -- |
| 2019-05-30 | Himes (Vaughn B) | Chief Technology Officer | Buy | 8000 | 12.00 |
| 2019-05-30 | Himes (Vaughn B) | Chief Technology Officer | Sell | 2560 | 66.50 |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Capital Bank & Trust Co (Albany New York) | 1174026 | 0.73% | 55400 | 4.95% | 2019-03-31 |
| T. Rowe Price Associates, Inc. | 8094701 | 5.02% | 19961 | 0.25% | 2019-03-31 |
| BlackRock Inc | 9203833 | 5.71% | 98852 | 1.09% | 2019-03-31 |
| Vanguard Group Inc | 9261066 | 5.74% | 16118 | 0.17% | 2019-03-31 |
| Capital Research & Mgmt Co - Division 3 | 12896169 | 7.99% | 1008087 | 8.48% | 2019-03-31 |
| Capital Research and Management Company | 14123456 | 8.73% | 985377 | 7.50% | 2019-07-31 |
| PRIMECAP Management Company | 14231300 | 8.82% | 96100 | 0.68% | 2019-03-31 |
| Wellington Management Company LLP | 14728336 | 9.13% | -410631 | -2.71% | 2019-03-31 |
| Baker Bros Advisors LP | 51049760 | 31.65% | 3700 | 0.01% | 2019-03-31 |
| Baillie Gifford & Co Limited. | 6683336 | 4.14% | -38424 | -0.57% | 2019-03-31 |
| Hartford Funds Management Company, LLC | 3967755 | 2.45% | -23963 | -0.60% | 2019-07-31 |
| State Street Corporation | 3260085 | 2.02% | 328971 | 11.22% | 2019-03-31 |
| Geode Capital Management, LLC | 1181056 | 0.73% | -1051058 | -47.09% | 2019-03-31 |
| Vanguard | 1222801 | 0.76% | -166028 | -11.95% | 2019-07-31 |
| Frontier Capital Management CO Inc | 1258153 | 0.78% | 91185 | 7.81% | 2019-03-31 |
| Capital Guardian Trust Company | 1358254 | 0.84% | 17204 | 1.28% | 2019-03-31 |
| First Trust Advisors L.P. | 1505850 | 0.93% | -505264 | -25.12% | 2019-03-31 |
| Vanguard Investments Australia Ltd | 2918336 | 1.80% | 501 | 0.02% | 2019-07-31 |
| Matrix Capital Management Company, LLC | 3141852 | 1.95% | -- | -- | 2019-03-31 |
| BlackRock Fund Advisors | 3217398 | 1.99% | 19480 | 0.61% | 2019-07-31 |
| Manning & Napier Group, LLC | 1625891 | 1.01% | 135280 | 9.08% | 2018-12-31 |
| Goldman Sachs Group Inc | 1309792 | 0.81% | -399317 | -23.36% | 2018-12-31 |
| Fidelity Management and Research Company | 1115956 | 0.70% | -470746 | -29.67% | 2018-09-30 |
| FMR Inc | 1115956 | 0.70% | -470746 | -29.67% | 2018-09-30 |
| Fidelity Management & Research Company | 1227627 | 0.77% | -938516 | -43.33% | 2018-11-30 |
| Goldman, Sachs & Co. | 1339933 | 0.84% | -564657 | -29.65% | 2018-09-30 |
| BlackRock Institutional Trust Company NA | 2988054 | 1.87% | -156518 | -4.98% | 2018-06-30 |
| State Street Corp | 2877791 | 1.81% | -263113 | -8.38% | 2018-06-30 |
| Citadel Advisors Llc | 1333126 | 0.84% | 374461 | 39.06% | 2018-06-30 |
| Point72 Asset Management, L.P. | 1262848 | 0.80% | 1262848 | -- | 2018-06-30 |
| Goldman Sachs Asset Management LP | 1019627 | 0.64% | -5187 | -0.51% | 2018-06-30 |
| Mitsubishi UFJ Trust & Banking Corp | 1005658 | 0.63% | -48524 | -4.60% | 2018-06-30 |
| OppenheimerFunds Inc | 1000153 | 0.63% | -- | -- | 2018-03-31 |
| Wasatch Advisors Inc. | 973379 | 0.62% | -6014 | -0.61% | 2018-03-31 |
| NORGES BANK | 1010749 | 0.70% | 138494 | 15.88% | 2017-12-31 |
| Pictet Asset Management SA | 1182508 | 0.82% | -83918 | -6.63% | 2017-12-31 |
| Redmile Group, LLC | 1156021 | 0.80% | -687712 | -37.30% | 2017-12-31 |
| Manning & Napier Advisors, LLC | 2574895 | 1.79% | 2574895 | -- | 2017-09-30 |
| Pinnacle Associates Inc | 930673 | 0.64% | -75279 | -7.48% | 2017-12-31 |
| Artisan Partners Limited Partnership | 4104329 | 2.90% | -101775 | -2.42% | 2016-09-30 |
| Eventide Asset Management, LLC | 835506 | 0.59% | -- | -- | 2016-09-30 |
| Baillie Gifford Life Limited | 794531 | 0.56% | -- | -- | 2016-12-31 |
| Baillie Gifford & Co. | 15238601 | 3.00% | 592172035 | 0.10% | 1999-11-30 |
| FMR LLC | 18583737 | 3.00% | 722164020 | 0.20% | 1999-11-30 |
| Felix J. Baker, Ph.D. Baker Bros. Advisors LP and Affiliates (3) | 29112227 | 3.00% | 1131301141 | 0.20% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| SPDR | 821096 | 0.51% | 12765 | 1.58% | 2019-07-31 |
| Vanguard Capital Opportunity Fund | 2551200 | 1.58% | 98700 | 4.02% | 2019-03-31 |
| Vanguard Mid-Cap Index Fund | 2554241 | 1.58% | 48193 | 1.92% | 2019-06-30 |
| Vanguard Total Stock Market Index Fund | 2876174 | 1.78% | 521 | 0.02% | 2019-06-30 |
| Vanguard Health Care Fund | 3140767 | 1.94% | -- | -- | 2019-03-31 |
| American Funds New Perspective Fund | 3545180 | 2.19% | -198723 | -5.31% | 2019-06-30 |
| PrimeCap Odyssey Aggressive Growth Fund | 4196200 | 2.59% | 5000 | 0.12% | 2019-06-30 |
| PrimeCap Odyssey Growth Fund | 5992700 | 3.71% | -33000 | -0.55% | 2019-06-30 |
| American Funds Growth Fund of Amer | 6802100 | 4.21% | 979300 | 16.82% | 2019-06-30 |
| Hartford MidCap Fund | 2395673 | 1.48% | -20802 | -0.86% | 2019-06-30 |
| T. Rowe Price Mid-Cap Growth Fund | 2000000 | 1.24% | 150000 | 8.11% | 2019-06-30 |
| American Funds Fundamental Invs | 1607600 | 0.99% | 393600 | 32.42% | 2019-06-30 |
| T. Rowe Price Mid-Cap Value Fund | 872482 | 0.54% | -35300 | -3.89% | 2019-06-30 |
| T. Rowe Price Health Sciences Fund | 895421 | 0.55% | -61700 | -6.45% | 2019-06-30 |
| Columbia Acorn Fund | 925000 | 0.57% | 275000 | 42.31% | 2019-06-30 |
| Vanguard US Opportunities Fund | 1003300 | 0.62% | -20000 | -1.95% | 2019-06-30 |
| First Trust NYSE Arca Biotech Fund | 1263563 | 0.78% | -3045 | -0.24% | 2019-07-31 |
| Vanguard Extended Market Index Fund | 1491561 | 0.92% | -363 | -0.02% | 2019-06-30 |
| American Funds IS | 1536306 | 0.95% | -- | -- | 2019-06-30 |
| iShares Nasdaq Biotechnology ETF | 1592428 | 0.98% | 16573 | 1.05% | 2019-07-30 |
| Vanguard Growth Index Fund | 749251 | 0.46% | 27171 | 3.76% | 2019-06-30 |
| T. Rowe Price New Horizons Fund | 766601 | 0.48% | 119800 | 18.52% | 2019-03-31 |
| Fidelity | 774890 | 0.48% | -82300 | -9.60% | 2019-04-30 |
| BlackRock Health Sciences Opps Port | 1027218 | 0.64% | -- | -- | 2019-03-31 |
| VA CollegeAmerica New Perspective Fd | 3743903 | 2.33% | -- | -- | 2018-12-31 |
| VA CollegeAmerica The Gr Fd of Amer | 5460200 | 3.40% | 5460200 | -- | 2018-12-31 |
| Oppenheimer Global Opportunities Fund | 1000000 | 0.62% | -- | -- | 2018-04-30 |
| Vanguard Small Cap Index | 1300122 | 0.81% | 7060 | 0.55% | 2018-08-31 |
| Vanguard Small Cap Index Fund | 1300122 | 0.81% | 7060 | 0.55% | 2018-08-31 |
| T. Rowe Price Mid-Cap Value | 1706582 | 1.08% | -62600 | -3.54% | 2018-06-30 |
| BlackRock Health Sciences Opps Inv A | 908118 | 0.57% | -- | -- | 2018-07-31 |
| T. Rowe Price New Horizons | 1101001 | 0.69% | 113213 | 11.46% | 2018-06-30 |
| PRIMECAP Odyssey Aggressive Growth | 4205500 | 2.65% | 15000 | 0.36% | 2018-06-30 |
| VA CollegeAmerica New Perspective 529E | 3743903 | 2.36% | -- | -- | 2018-06-30 |
| Vanguard Total Stock Mkt Idx | 2581461 | 1.63% | 2760 | 0.11% | 2018-07-31 |
| Vanguard Capital Opportunity Inv | 2424900 | 1.53% | 15000 | 0.62% | 2018-06-30 |
| iShares Nasdaq Biotechnology | 1795150 | 1.13% | -3417 | -0.19% | 2018-09-12 |
| T. Rowe Price Mid-Cap Growth | 1963743 | 1.24% | 213743 | 12.21% | 2018-06-30 |
| Vanguard Health Care Inv | 1911900 | 1.21% | -- | -- | 2018-06-30 |
| American Funds NVIT Growth-Income II | 1536306 | 0.97% | -- | -- | 2018-06-30 |
| Vanguard Extended Market Idx Inv | 1401098 | 0.88% | 11347 | 0.82% | 2018-07-31 |
| T. Rowe Price Health Sciences | 1474006 | 0.93% | 320503 | 27.79% | 2018-06-30 |
| Hartford MidCap A | 1279816 | 0.81% | 365811 | 40.02% | 2018-07-31 |
| Vanguard Mid Cap Index I | 1219986 | 0.77% | 9107 | 0.75% | 2018-07-31 |
| First Trust NYSE Arca Biotech ETF | 1057230 | 0.67% | -- | -- | 2018-09-13 |
| PRIMECAP Odyssey Growth | 6118700 | 3.86% | 10000 | 0.16% | 2018-06-30 |
| Vanguard Small Cap Growth Index Inv | 727952 | 0.46% | 21600 | 3.06% | 2018-06-30 |
| Oppenheimer Global Opportunities A | 1000000 | 0.63% | -- | -- | 2018-04-30 |
| Fidelity Advisor | 501220 | 0.35% | -58100 | -10.39% | 2017-11-30 |
| Columbia Acorn Z | 522621 | 0.36% | -82553 | -13.64% | 2017-11-30 |
| Fidelity Spartan | 433653 | 0.30% | -- | -- | 2017-10-31 |
| Artisan Mid Cap Investor | 1028585 | 0.73% | -941090 | -47.78% | 2016-12-31 |
| Wasatch Small Cap Growth Investor | 916842 | 0.65% | -80145 | -8.04% | 2016-12-31 |
| Eventide Gilead N | 640206 | 0.45% | -- | -- | 2016-09-30 |
| Wasatch Core Growth | 651027 | 0.46% | -- | -- | 2016-12-31 |
| Oppenheimer Global Opportunities | 1400000 | 1.00% | -- | -- | 2015-09-30 |
| Fidelity® OTC Portfolio | 1648886 | 1.20% | -- | -- | 2015-09-30 |
| Artisan Mid Cap Fund | 1671216 | 1.20% | 634941 | 61.30% | 2015-09-30 |
| Fidelity® Series Growth Company Fund | 1857917 | 1.30% | -136900 | -6.90% | 2015-09-30 |
| Fidelity® Select Biotechnology Portfolio | 3203831 | 2.30% | 770200 | 31.60% | 2015-09-30 |
| Fidelity® Growth Company Fund | 6556136 | 4.70% | -560500 | -7.90% | 2015-09-30 |
| Felix James Baker | Dr. Felix J. Baker is an Independent Director at Alexion Pharmaceuticals, Inc., an Independent Director at Genomic Health, Inc., a Lead Independent Director at Seattle Genetics, Inc., a Co-Managing Member at Baker Bros. Advisors LP, a Manager at Fbb2 LLC, a Managing Partner at Baker Bros. Advisors GP LLC and a Partner at FBB Associates. He is on the Board of Directors at Alexion Pharmaceuticals, Inc., Genomic Health, Inc. and Seattle Genetics, Inc. Dr. Baker was previously employed as a Chairman by Synageva BioPharma Corp., an Independent Director by Ardea Biosciences, Inc., a Chairman by Synageva BioPharma Corp. /Old/, and an Owner by VaxGen, Inc. He also served on the board at Trimeris, Inc., ConjuChem Biotechnologies, Inc. /Old/, Neurogen Corp., ConjuChem, Inc., AnorMED, Inc., Aquinox Pharmaceuticals, Inc., ConjuChem Biotechnologies, Inc., Presidio Pharmaceuticals, Inc. and SlipChip Corp. He received his undergraduate degree from Stanford University and a doctorate degree from Stanford University. |
|---|---|
| Srinivas Akkaraju | Dr. Srinivas Akkaraju is an Independent Director at Syros Pharmaceuticals, Inc., a Principal at Samsara Biocapital, LLC, an Independent Director at ZS Pharma, Inc., an Independent Director at Intercept Pharmaceuticals, Inc., an Independent Director at Seattle Genetics, Inc. and a Chairman at Aravive, Inc. He is on the Board of Directors at Syros Pharmaceuticals, Inc., ZS Pharma, Inc., Intercept Pharmaceuticals, Inc., Seattle Genetics, Inc., A2 Biotherapeutics, Inc., Mirobio Ltd. and The George Institute for Global Health. Dr. Akkaraju was previously employed as an Independent Director by aTyr Pharma, Inc., a Chairman by Versartis, Inc., a Managing General Partner by Sofinnova Ventures, Inc., a Managing Director by New Leaf Venture Partners LLC, an Independent Director by Pharmos Corp., a Managing Director by Panorama Capital LLC, a Partner by J.P. Morgan Partners LLC, a Senior Manager by Genentech, Inc., a Member by BioStreet, Inc., and an Independent Director by Principia Biopharma, Inc. He also served on the board at Amarin Corp. Plc, Phenomix Corp., Barrier Therapeutics, Inc., Eyetech Pharmaceuticals, Inc., Itero Biopharmaceuticals, Inc., Pharmos, Inc., Piramed Ltd., Presidio Pharmaceuticals, Inc., Synageva BioPharma Corp. and Synageva BioPharma Corp. /Old/. He received his undergraduate degree from Rice University and a doctorate degree from Stanford University School of Medicine. |
| Jean I. Liu | Currently, Jean I. Liu holds the position of Executive VP-Legal Affairs & General Counsel at Seattle Genetics, Inc. Ms. Liu is also on the board of Cascadian Therapeutics, Inc. and Member of The State Bar of California. In her past career she held the position of Secretary, Vice President & General Counsel of Halozyme Therapeutics, Inc., Secretary & Chief Legal Officer of DURECT Corp., Attorney at Pillsbury Madison & Sutro LLP and Attorney at Venture Law Group. Ms. Liu received an undergraduate degree from the University of Michigan, a graduate degree from Stanford University and a graduate degree from Columbia University. |
| Vaughn B. Himes | Presently, Vaughn B. Himes is Chief Technical Officer at Seattle Genetics, Inc. In the past he occupied the position of Senior Vice President-Technical Operations at ZymoGenetics, Inc., Vice President-Worldwide Manufacturing at Corixa Corp., Vice President-Product Development at Genovo, Inc., Associate Director-Biological Development at Wyeth Lederle Vaccines SA and Vice President-Manufacturing Operations at AmpliPhi Biosciences Corp. Vaughn B. Himes received an undergraduate degree from Pomona College and a doctorate from the University of Minnesota. |
| David W. Gryska | David W. Gryska is on the board of Seattle Genetics, Inc., Aerie Pharmaceuticals, Inc. and PDL BioPharma, Inc. In his past career he was President, CEO, COO & Director at Myrexis, Inc., Chief Financial Officer & Executive Vice President of Incyte Corp., Chief Financial Officer & Senior Vice President of Celgene Corp., Principal at Strategic Consulting Group, Inc., Chief Financial Officer & Vice President for Cardiac Pathways Corp., Chief Financial Officer & Senior Vice President for Scios, Inc. and Audit Partner at Ernst & Young LLP. Mr. Gryska received an undergraduate degree from Loyola University of Chicago and an MBA from Golden Gate University. |
| Clay B. Siegall | Clay B. Siegall founded Seattle Genetics, Inc. Presently, he is Chairman, President & Chief Executive Officer at this company. Dr. Siegall is also on the board of 6 other companies. In his past career he was Principal Scientist at Bristol-Myers Squibb Pharmaceutical Research Institute. He received an undergraduate degree from the University of Maryland and a doctorate from George Washington University. |
| Peter D. Senter | Peter D. Senter is Affiliate Professor-Bioengineering at the University of Washington and Vice President-Chemistry at Seattle Genetics, Inc. In his past career Dr. Senter occupied the position of Chemistry Director at Cytokine Networks, Principal at Bristol-Myers Squibb Pharma Research Labs LLC, Principal at Harvard Medical School and Principal at Dana-Farber Cancer Institute, Inc. Peter D. Senter received a doctorate from the University of Illinois and an undergraduate degree from the University of California, Berkeley. |
| Marc E. Lippman | Marc E. Lippman founded Ascenta Therapeutics, Inc. and Aurora Biopharma, Inc. Dr. Lippman is on the board of Seattle Genetics, Inc. and Chief Scientific Advisor at Aurora Biopharma, Inc. and Chairman-Department of Medicine at The University of Miami Leonard M. Miller School of Medicine. In his past career he was Senior Advisor at Perseus LLC, Professor at the University of Michigan, Professor at Georgetown University, Head-Medical Breast Cancer Section at National Cancer Institute, Member of Alpha Omega Alpha Honor Medical Society, Deputy Director at Sylvester Comprehensive Cancer Center and Director at Ascenta Therapeutics, Inc. Dr. Lippman received a doctorate from Yale University and an undergraduate degree from Cornell University. |
| Eric L. Dobmeier | Mr. Eric L. Dobmeier is Chief Operating Officer at Seattle Genetics, Inc. He is on the Board of Directors at Versartis, Inc., Atara Biotherapeutics, Inc., Stemline Therapeutics, Inc. and Adaptive Biotechnologies Corp. Mr. Dobmeier was previously employed as a Principal by Heller Ehrman LLP and a Principal by Venture Law Group. He received his undergraduate degree from Princeton University and a graduate degree from Berkeley Law University of California. |
| Daniel G. Welch | Mr. Daniel G. Welch is Executive Partner at Sofinnova Ventures, Inc., Independent Director at Hyperion Therapeutics, Inc., and Independent Director at Seattle Genetics, Inc. He has over 30 years of experience across both multi-national pharmaceutical companies and biotech companies. Mr. Welch joined Sofinnova Ventures in 2015. Most recently, he was the Chairman, CEO and President of InterMune. Beginning in 2003, he led a comprehensive company turn-around, refocusing the company's development efforts. He built the InterMune development and commercial teams that delivered the successful approval of Esbriet. In October 2014, Roche acquired InterMune. From August 2002 to January 2003, he served as Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc., a pharmaceutical company. From October 2000 to June 2002, he served as president of the pharmaceutical division of Elan Corporation, PLC (acquired by Perrigo). From September 1987 to August 2000, he served in various senior management roles at Sanofi-Synthelabo (now Sanofi) and its predecessor companies Sanofi and Sterling Winthrop. During his time at Sanofi, he led the successful worldwide launches of Plavix, Eloxatin and Avapro as Vice President of Worldwide Marketing and he served as COO of the U.S. business. From November 1980 to September 1987, he was with American Critical Care, a division of American Hospital Supply. Mr. Welch holds a B.S. from the University of Miami and an M.B.A. from the University of North Carolina. |
| Todd E. Simpson | Mr. Todd E. Simpson, CPA, is an Independent Director at Aquinox Pharmaceuticals, Inc. and a Chief Financial & Accounting Officer at Seattle Genetics, Inc. He is on the Board of Directors at Cascadian Therapeutics, Inc., Washington Biotechnology & Biomedical Association, Aquinox Pharmaceuticals, Inc. and Neoleukin Therapeutics, Inc. Mr. Simpson was previously employed as a CFO, Vice President-Finance & Administration by Targeted Genetics Corp., a Chief Financial Officer & VP-Administration by Aastrom Biosciences, Inc., a Treasurer by Integra LifeSciences Holdings Corp., a Chief Financial Officer & Vice President-Finance by Telios Pharmaceuticals, Inc., and a Principal by Ernst & Young LLP. He received his undergraduate degree from Oregon State University. |
| Nancy A. Simonian | Currently, Nancy A. Simonian holds the position of President, Chief Executive Officer & Director at Syros Pharmaceuticals, Inc. She is also on the board of Seattle Genetics, Inc., Biotechnology Innovation Organization, The Damon Runyon Cancer Research Foundation and Evelo Biosciences, Inc. In her past career she was Vice President-Clinical Development at Biogen, Inc., Chief Medical Officer & SVP-Regulatory Affairs at Takeda Oncology Co., Faculty Member at The General Hospital Corp., Assistant Professor at Massachusetts General Hospital Cancer Center and Assistant Professor at Harvard Medical School. Dr. Simonian received an undergraduate degree from Princeton University and a doctorate from Perelman School of Medicine. |
| Jonathan Drachman | Dr. Jonathan Drachman, MD, is an Independent Director at Calithera Biosciences, Inc. and a Chief Medical Officer, EVP-Research & Development at Seattle Genetics, Inc. He is on the Board of Directors at Calithera Biosciences, Inc. Dr. Drachman was previously employed as a Faculty Member by University of Washington and a Senior Investigator by Bloodworks Northwest. He received his undergraduate degree from Harvard University and a doctorate degree from Harvard Medical School. |
| Christopher Pawlowicz | Presently, Christopher Pawlowicz holds the position of Executive Vice President-Human Resources at Seattle Genetics, Inc. He previously was Senior VP-Human Resources & Administration at MedPointe, Inc., Director-Human Resources of Monsanto Co., Executive Director-Human Resources at G.D. Searle & Co., Inc., Executive Director-Human Resources at Pharmacia Corp. and Vice President-Human Resources of Express Scripts, Inc. He received an undergraduate degree from Benedictine College and a graduate degree from the University of Illinois. |
| John A. Orwin | Currently, John A. Orwin holds the position of President, Chief Executive Officer & Director at Atreca, Inc. He is also on the board of Array BioPharma, Inc., Seattle Genetics, Inc., Biotechnology Innovation Organization and Retrophin, Inc. In the past John A. Orwin occupied the position of Chairman for Affymax, Inc., Franchise Vice President-Oncology at Johnson & Johnson Vice President-Oncology Franchise at Centocor Ortho Biotech, Inc. and Marketing Director-Oncology Division at ALZA Corp. (both are subsidiaries of Johnson & Johnson), Independent Director at NeurogesX, Inc., Chief Executive Officer & Director at Relypsa, Inc., Senior Vice President-BioOncology Business Unit at Genentech, Inc., Product Manager-Oncology Division at Schering-Plough Corp., Vice President-Marketing for SangStat Medical Corp. and Marketing Director of Rhone-Poulenc Rorer Pharmaceuticals, Inc. Mr. Orwin received an undergraduate degree from Rutgers State University of New Jersey and an MBA from New York University. |
| Daniel G. Welch | Mr. Daniel G. Welch is Executive Partner at Sofinnova Ventures, Inc., Independent Director at Hyperion Therapeutics, Inc., and Independent Director at Seattle Genetics, Inc. He has over 30 years of experience across both multi-national pharmaceutical companies and biotech companies. Mr. Welch joined Sofinnova Ventures in 2015. Most recently, he was the Chairman, CEO and President of InterMune. Beginning in 2003, he led a comprehensive company turn-around, refocusing the company's development efforts. He built the InterMune development and commercial teams that delivered the successful approval of Esbriet. In October 2014, Roche acquired InterMune. From August 2002 to January 2003, he served as Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc., a pharmaceutical company. From October 2000 to June 2002, he served as president of the pharmaceutical division of Elan Corporation, PLC (acquired by Perrigo). From September 1987 to August 2000, he served in various senior management roles at Sanofi-Synthelabo (now Sanofi) and its predecessor companies Sanofi and Sterling Winthrop. During his time at Sanofi, he led the successful worldwide launches of Plavix, Eloxatin and Avapro as Vice President of Worldwide Marketing and he served as COO of the U.S. business. From November 1980 to September 1987, he was with American Critical Care, a division of American Hospital Supply. Mr. Welch holds a B.S. from the University of Miami and an M.B.A. from the University of North Carolina. |
| Peggy Pinkston | Currently, Peggy Pinkston is Vice President-Investor Relations at Seattle Genetics, Inc. She previously held the position of Director-Investor Relations at aQuantive, Inc. |
| Darren S. Cline | Darren S. Cline is on the board of Cascadian Therapeutics, Inc. and Stemline Therapeutics, Inc. and Executive Vice President-Commercial at Seattle Genetics, Inc. Mr. Cline previously was Executive Director-Sales at Alexion Pharmaceuticals, Inc., Marketing Director of Amgen, Inc. and Vice President-Market Access at InterMune, Inc. Mr. Cline received an undergraduate degree from San Diego State University and an MBA from Pepperdine University. |
| Natasha A. Hernday | Natasha A. Hernday is on the board of PDL BioPharma, Inc. and Senior Vice President-Corporate Development at Seattle Genetics, Inc. In the past Ms. Hernday held the position of Director-Corporate Development at Amgen, Inc. Ms. Hernday received an MBA from Pepperdine University and an undergraduate degree from the University of California, Santa Barbara. |
| Tricia Larson | Presently, Tricia Larson occupies the position of Media Contact at Seattle Genetics, Inc. In her past career she was Director-Corporate Communications at Dendreon Corp. |
| Robert J. Lechleider | Currently, Robert J. Lechleider holds the position of Senior Vice President-Clinical Development at Seattle Genetics, Inc. In his past career he held the position of Chief Scientific Officer of USDS, Inc. and Associate Professor at Georgetown University. Dr. Lechleider received an undergraduate degree from Princeton University and a doctorate from the University of Illinois College of Medicine. |
| Jean I. Liu | Currently, Jean I. Liu holds the position of Executive VP-Legal Affairs & General Counsel at Seattle Genetics, Inc. Ms. Liu is also on the board of Cascadian Therapeutics, Inc. and Member of The State Bar of California. In her past career she held the position of Secretary, Vice President & General Counsel of Halozyme Therapeutics, Inc., Secretary & Chief Legal Officer of DURECT Corp., Attorney at Pillsbury Madison & Sutro LLP and Attorney at Venture Law Group. Ms. Liu received an undergraduate degree from the University of Michigan, a graduate degree from Stanford University and a graduate degree from Columbia University. |
| Dennis Benjamin | Dennis Benjamin is Senior Vice President-Translational Research at Seattle Genetics, Inc. Dr. Benjamin received an undergraduate degree from Massachusetts Institute of Technology Portugal and a doctorate from the University of California. |
| Alpna Seth | Currently, Alpna Seth holds the position of Chief Operating Officer of Vir Biotechnology, Inc. He is also on the board of Bio-Techne Corp., Seattle Genetics, Inc. and Women in Bio, Inc. In the past Dr. Seth was Senior VP & Global Head-Biosimilars Business at Biogen, Inc. He received a doctorate from the University of Massachusetts Medical School. |
| Roger D. Dansey | Currently, Roger D. Dansey holds the position of Chief Medical Officer at Seattle Genetics, Inc. In the past he held the position of Vice President-Oncology Clinical Research at Gilead Sciences, Inc. and SVP & Head-Therapeutic Area at Merck Research Laboratories. Dr. Dansey received a doctorate from the University of the Witwatersrand. |
| Robin G. Taylor | Robin G. Taylor is Chief Commercial Officer at Seattle Genetics, Inc. Dr. Taylor received an MBA from the University of California, Berkeley, an undergraduate degree from the University of British Columbia and a doctorate from the University of Toronto. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 1
百济神州与Seattle Genetics宣布，双方就一款先进的临床前肿瘤候选药物达成许可协议。